Windward Bio IPO: OrbiMed fund buys 1.18M shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Windward Bio Group AG (WWB) reported an IPO purchase and related preferred-share conversions and warrant exercise involving OrbiMed Private Investments IX, LP (OPI IX). On November 16, 2026, David P. Bonita, a director and 10% owner, reported transactions involving securities held of record by OPI IX. OPI IX purchased 1,176,471 common shares at $17.00 per share in the initial public offering. Its 3,561,936 Series A and 1,611,008 Series B Preferred Shares converted one-for-one into common shares immediately before the IPO closing, and it exercised warrants for 216,668 common shares at $0.02 per share. The report also lists 232 shares delivered or withheld for payment of exercise price or tax liability; a footnote says they were withheld in connection with the warrant exercise. It lists a direct stock option covering 22,675 common shares for Bonita, with a $17.00 exercise price and vesting in 12 equal monthly installments beginning December 31, 2026, subject to continuous service. Bonita disclaimed beneficial ownership except to the extent of any pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Preferred Shares F4, F2, F3 | 3,561,936 | $0.00 | $0.00 |
| Conversion | Series B Preferred Shares F4, F2, F3 | 1,611,008 | $0.00 | $0.00 |
| Exercise | Warrants (right to buy) F5, F7, F2, F3 | 216,668 | $0.00 | $0.00 |
| Purchase | Common Shares F1, F2, F3 | 1,176,471 | $17.00 | $20.00M |
| Conversion | Common Shares F4, F2, F3 | 3,561,936 | -- | -- |
| Conversion | Common Shares F4, F2, F3 | 1,611,008 | -- | -- |
| Exercise | Common Shares F5, F2, F3 | 216,668 | $0.02 | $4K |
| Exercise Price or Tax Liability | Common Shares F6, F2, F3 | 232 | $17.00 | $4K |
| Holding | Stock Option (right to buy) F8 | -- | -- | -- |
Footnotes (8)
- F1. Reflects Common Shares of the Issuer purchased in the Issuer's initial public offering.
- F2. These securities are held of record by OrbiMed Private Investments IX, LP. ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. The Reporting Person is a member of OrbiMed Advisors.
- F3. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
- F4. Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
- F5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
- F6. Reflects Common Shares withheld in connection with the Reporting Person's exercise of warrants.
- F7. The warrants are fully vested and exercisable.
- F8. These options will vest in 12 equal monthly installments on the last day of the relevant month commencing on December 31, 2026, subject to the Reporting Person's continuous service as of each such vesting date.
Key Figures
Key Terms
initial public offering financial
voting and investment power regulatory
beneficial ownership regulatory
fully vested and exercisable technical
continuous service technical
1-to-1 basis technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were the terms of OPI IX's WWB warrant exercise?
What is the vesting schedule for David P. Bonita's WWB stock options?
AI-generated analysis. How Rhea-AI works. Not financial advice.